Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies

Pediatric Hematology and Oncology

Volumn 31, Issue 8, 2014, Pages 754-764

  Sawada, Akihisa ^a   Shimizu, Mariko ^a   Isaka, Kanako ^a   Higuchi, Kouhei ^a   Mayumi, Azusa ^a   Yoshimoto, Yuri ^a   Kikuchi, Hiroaki ^a   Kondo, Osamu ^a   Koyama Sato, Maho ^a   Yasui, Masahiro ^a   Kawa, Keisei ^a   Inoue, Masami ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

Cyclophosphamide; HLA haploidentical HSCT; Pediatrics; PTCY

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; MELPHALAN; MERCAPTOPURINE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS ANTIGENEMIA; BK VIRUS INFECTION; BONE MARROW TRANSPLANTATION; BRONCHIOLITIS OBLITERANS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CYTOMEGALOVIRUS ANTIGENEMIA; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG DOSE REDUCTION; DRUG FEVER; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HLA HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JUVENILE MYELOMONOCYTIC LEUKEMIA; KIDNEY FAILURE; LONG TERM CARE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; MIXED PHENOTYPE ACUTE LEUKEMIA; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIPLE ORGAN FAILURE; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SEPSIS; SPLEEN ABSCESS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ALLOTRANSPLANTATION; BLOOD; COMPLICATION; GRAFT VS HOST DISEASE; HAPLOIDY; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; JAPAN; NEOPLASMS;

CHILD; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HAPLOIDY; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; NEOPLASMS; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84909982046     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2014.961214     Document Type: Article

References (27)

1. Ogawa H, Ikegame K, Kaida K, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1-8.
2. Inoue M, Nakano T, Yoneda A, et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bonemarrow transplantation. Bone Marrow Transplant. 2003;32:103-106.
3. Koscielniak E, Gross-Wieltsch U, Treuner J, et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patientwith relapse of metastatic disease. J Clin Oncol. 2005;23:242-244.
4. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447-3454.
5. Lu DP, Dong L,Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065-3073.
6. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291-297.
7. ODonnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377-836.
8. Luznik L, ODonnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641-650.
9. Ciurea SO,Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1835-1844.
10. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117-122.
11. Solomon SR, Sizemore CA, SanacoreM, et al.Haploidentical transplantation using T cell replete peripheral blood stem cells andmyeloablative conditioning in patientswith high-riskhematologicmalignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18:1859-1866.
12. http://evs.nci.nih.gov/ftp1/CTCAE/About.html
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
14. Takagi S,Masuoka K, Uchida N, et al. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol. 2009;147:543-553.
15. Koyama M, Sawada A, Yasui M, et al. Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2007;86:466-467.
16. Sawada A, Koyama-SatoM, Yasui M, et al.Multiplex polymerase chain reaction for six herpesviruses after hematopoietic stem cell transplantation. Pediatr Int. 2011;53:1010-1017.
17. Przepiorka D,WeisdorfD,Martin P, et al. Consensus conference on acuteGVHDgrading. Bone Marrow Transplant. 1995;15:825-828.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
19. Inoue M, Okamura T, Yasui M, et al. Increased intensity of acute graft-versus-host disease after reduced-intensity bonemarrow transplantation compared to conventional transplantation from an HLA-matched sibling in children. Bone Marrow Transplant. 2006;37:601-605.
20. Inoue M, Yasui M, Sawada A, et al. Encouraging results of stem cell transplantation following a melphalan-preceding intensified preparative regimen for refractory acute leukemia in children. Rinsho Ketsueki. 2007;48:1470-1477.
21. Kobbe G, Fenk R, Neumann F, et al. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy. 2004;6:533-542.
22. Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124:638-644.
23. Grosso D, Carabasi M, Filicko-OHara J, et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood. 2011;118:4732-4739.
24. Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res. 2004;10:3586-3592.
25. Kakodkar NC, Peddinti RR, Tian Y, et al. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012;59:642-647.
26. Yamada K, Yasui M, Kondo O, et al. Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:E60-E62.
27. Adriana S, Valeria CG, RoseaneG, et al.Haploidentical hematopoietic stem cell transplantationwith reduced intensity conditioning, T-cell replete grafts and post-transplant cyclophosphamide in pediatrics. Blood. 2013;122:5510.